Charles River Laboratories International, Inc. (NYSE:CRL) – Investment analysts at First Analysis lifted their FY2017 earnings estimates for Charles River Laboratories International in a research report issued to clients and investors on Monday. First Analysis analyst T. Van. Fleet now expects that the medical research company will post earnings per share of $5.15 for the year, up from their prior estimate of $5.05. First Analysis also issued estimates for Charles River Laboratories International’s Q4 2017 earnings at $1.26 EPS.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. The firm had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business’s revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 earnings per share.

A number of other analysts have also issued reports on the stock. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. Bank of America lowered their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research note on Tuesday, October 24th. Royal Bank of Canada initiated coverage on shares of Charles River Laboratories International in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price objective for the company. Finally, ValuEngine lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $110.21.

Shares of Charles River Laboratories International (NYSE:CRL) opened at $109.74 on Wednesday. The stock has a market cap of $5,136.36, a price-to-earnings ratio of 21.31, a PEG ratio of 1.73 and a beta of 0.89. Charles River Laboratories International has a one year low of $73.81 and a one year high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88.

A number of institutional investors have recently made changes to their positions in CRL. Canada Pension Plan Investment Board raised its holdings in Charles River Laboratories International by 11.7% in the second quarter. Canada Pension Plan Investment Board now owns 14,300 shares of the medical research company’s stock worth $1,446,000 after purchasing an additional 1,500 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Charles River Laboratories International by 1.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 267,203 shares of the medical research company’s stock worth $27,028,000 after purchasing an additional 4,865 shares in the last quarter. Arizona State Retirement System raised its holdings in Charles River Laboratories International by 2.0% in the second quarter. Arizona State Retirement System now owns 20,100 shares of the medical research company’s stock worth $2,033,000 after purchasing an additional 400 shares in the last quarter. State of Wisconsin Investment Board bought a new position in Charles River Laboratories International in the second quarter worth about $950,000. Finally, Alps Advisors Inc. raised its holdings in Charles River Laboratories International by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock worth $541,000 after purchasing an additional 14 shares in the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last ninety days, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,056,776 shares valued at $2,011,952. 2.20% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Charles River Laboratories International, Inc. Increased by First Analysis (CRL)” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-charles-river-laboratories-international-inc-increased-by-first-analysis-crl/1774348.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.